
PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5:

A61K 9/28, B05B 5/08 B05D 1/06

(11) International Publication Number:

WO 92/14451

A1

(43) International Publication Date:

3 September 1992 (03.09.92)

(21) International Application Number:

PCT/GB92/00323

(22) International Filing Date:

21 February 1992 (21.02.92)

(30) Priority data:

9103711.9

22 February 1991 (22.02.91)

(71) Applicant (for all designated States except US): HOECHST UK LIMITED [GB/GB]; Hoechst House, Salisbury Road, Hounslow MK7 7AJ (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): STANIFORTH, John, Nicholas [GB/GB]; High Trees, 170 Bloomfield Road, Bath, Avon BA2 2AT (GB). GROSVENOR, Martin, Paul [GB/GB]; 23 Stirtingale Avenue, Bath, Avon BA2 2NQ (GB).

(74) Agents: BARDO, Julian, Eason et al.; Abel & Imray, Northumberland House, 303-306 High Holborn, London WCIV 7LH (GB).

(81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE, DE (European patent), DK, OAPI patent), CS, DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC (European patent), MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, RU, SD, SE, SE (European patent), SN (OAPI patent), TD (OAPI patent), TG pean patent), SN (OAPI patent), TD (OAPI patent), TG (OAPI patent), US.

Published

With international search report.

Before the expiration of the time limit for amending the s, claims and to be republished in the event of the receipt of amendments.

(54) Title: IMPROVEMENTS IN OR RELATING TO ELECTROSTATIC COATING OF SUBSTRATES OF MEDICINAL PRODUCTS

(57) Abstract

7:

A method of coating substrates of medicinal products with a dry powder includes the following steps: feeding the medicinal substrates onto a conveying means (1); supplying the dry powder to a region (5) through which the substrates are to be conveyed; conveying the medicinal substrates on the conveying means (1) through the region (5) with the conveying means and/or the substrates maintained at a different electric potential from the dry powder, whereby the dry powder is attracted to the exposed surfaces of the substrates but is unable to reach the coated surfaces of the substrates in contact with the conveying means, and treating the dry powder coatings to convert the powder into a fused film secured to the substrates.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	мі	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barhados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
8F	Burkina Faso	GN	Guinea	NI.	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
ВJ	Benin	HU	Hungary	PL.	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JР	Japan	SD	Sudan
CC	Congo	KP	Democratic People's Republic	SE	Sweden
CH	Switzerland		of Korea	SN	Senegal
CF	Côte d'Ivoire	KR	Republic of Korea	SU	Soviet Union
CM	Cameroon	LI	Liechtenstein	TO	Chad
CS	Czechosłovakia	LK	Sri Lanka	TG	Togo
DE	Germany	LU	Luxembourg	US	United States of America
OK	Denmark	MC	Monaco		
ES	Spain	MG	Madagascar		

Improvements in or relating to Electrostatic Coating of Substrates of Medicinal Products

The present invention relates to a method and apparatus for electrostatic coating of substrates of medicinal products. The invention is particularly, but not exclusively, concerned with the coating of pharmaceutical tablet cores with a dry powder.

Proposals for electrostatic coating of tablets have been made for at least the last thirty years or so. example, GB-1075404 (published in 1967) proposes an 10 apparatus for coating tablets in which a liquid is sprayed onto one face of each tablet core as the tablet cores are conveyed below a first stage sprayer having an associated high voltage grid, the coating is dried, the coated cores are then conveyed below a second stage sprayer having an associated high voltage grid with the other side of the tablets uppermost, and then that coating is dried again.

15

Various paper proposals for electrostatically 20 coating tablet cores with a liquid or a dry powder have been made but as yet at least in the case of pharmaceutical tablets there is no recognized electrostatic coating method or apparatus that has proved sufficiently successful to be applied commercially on a reasonable 25 scale. While there are rotary tablet presses capable of producing pharmaceutical tablet cores continuously at a rate of for example 5,000 tablets per minute, the

subsequent coating of the tablet cores is most commonly carried out as a batch process by applying a liquid coating in a revolving drum.

In order to provide a commercially viable apparatus or method for coating medicinal products various problems must be overcome. It is in many ways easier to apply a liquid rather than a dry powder as the coating material and therefore, although both options have been considered in research, workers have favoured the use of liquids. 10 If a dry powder is applied then it is harder to obtain adhesion of the coating to the substrate, which is not itself likely to be sufficiently electrically conducting, even when the powder is electrostatically charged. order to provide a lasting bond between the substrate and 15 the powder, the powder must be transferred into a film, for example by melting, but in the case of a medicinal product, which in many cases will include organic materials, must not be damaged. Furthermore an even coating is required and it is very difficult to obtain an 20 even coating of powder on an electrically insulating medicinal substrate, even when the powder is electrostatically charged.

When liquid coating is used, the coating must be dried. Theoretically such drying could in some circum
stances be carried out at room temperature but in commercial practice it is important, for example because of the rate at which the process must be carried out, to heat the tablets and that is expensive because of the

WO 92/14451 PCT/GB92/00323

- · 3 -

large input of energy required to vapourize the solvent used in the liquid coating. Another disadvantage of liquid coating is that it cannot be used for coating materials that are not soluble or suitably dispersible in a usable liquid, preferably water.

It is an object of the invention to provide an improved method and apparatus for coating substrates of medicinal products.

According to the invention there is provided a

10 method of coating substrates of medicinal products with a
dry powder, the method including the following steps:

feeding the medicinal substrates onto a conveying means;

supplying the dry powder to a region through which

the medicinal substrates are to be conveyed on the

conveying means;

conveying the medicinal substrates on the conveying means through the region with the conveying means and/or the substrates maintained at a different electric

20 potential from the dry powder, whereby the dry powder is attracted to the exposed surfaces of the substrates but is unable to reach the surfaces of the substrates in contact with the conveying means, and

treating the dry powder coatings to convert the powder into a fused film secured to the substrates.

By placing the substrates on a conveying means during the charging process, it is found that a satisfactory spread of powder over the substrate can be obtained.

25

It is also found that some unevenness of distribution is not necessarily serious, even if it is important for the final tablet to have a coating of substantially constant thickness, because further levelling can take place when the powder is converted into a fused film. Thus the present invention enables a desired thickness of coating to be applied uniformly over a surface of a substrate. The thickness of the coating will typically be greater than 10 μ m. Although the present invention as defined above still involves the input of energy to convert the powder into a fused film, the amount of energy required can be substantially less than that involved in the case " where a liquid coating comprising a coating substance dissolved in a suitable solvent is applied and the solvent has to be vapourised after application of the 15 The method also removes the necessity for coating. solvent handling and disposal and for batch processing.

The medicinal products will usually be pharmaceutical tablets ("tablets" being as defined below) but 20 they may also be implants that are not administered orally.

While reference is made throughout the specification to "tablets" and the invention is of particular application to pharmaceutical tablets of conventional shape, it should be understood that the term is to be interpreted in a broad sense as covering also, for example, pellets, capsules or spherules.

While the method of the invention will generally be

applied to the coating of tablet cores (or substrates of the medicinal products) which have not received any coating since being formed in a press, it may be used to apply a coating on top of an already coated or partly coated tablet core.

The method of the present invention may be carried out as a continuous process. In practice there are considerable advantages in being able to operate the coating process continuously rather than as a batch process.

While there are certain applications, which will be referred to later, where it will be desired to coat the medicinal substrate on one side only or with at least one discontinuity in the coating, it will generally be desirable to coat all of the exterior of the tablet core. 15 Accordingly the method preferably comprises the following further subsequent steps:

feeding the medicinal substrates onto a conveying means with the treated powder coatings of the substrates in contact with the conveying means and with that surface 20 of the substrate that was in contact with the conveying means during the above-mentioned conveying step exposed;

supplying the dry powder with which the substrates are to be coated to a region through which the conveying means passes;

25 conveying the substrates on the conveying means through the region with the conveying means and/or the substrates maintained at a different electric potential from the dry powder whereby the dry powder is attracted to the exposed surfaces of the substrates but is unable to reach the coated surfaces of the substrates in contact with the conveying means, and

treating the dry powder coatings to convert the
newly applied powder into a fused film secured to the
substrates.

for practical convenience the conveying means used during the second coating stage is preferably not the one used during the first coating stage but it is possible to use the same conveying means for both coating stages.

The powder applied during each coating stage will usually be the same but it is of course possible to apply different powders at each stage; similarly the same thickness of coating will usually be applied at each stage but different thicknesses may be applied, if desired.

If desired still further coating stages may be employed for example to apply powder to sides of the products, if the sides have not already been coated.

Preferably the conveying means comprises a conveyor belt. The conveying means may however comprise an inclined static surface or a vibrated surface along which the substrates slide. The friction between the substrates and the inclined surface may be reduced by passing air through the inclined surface from the underside.

Converting the powder into a fused film may advantageously comprise converting the powder into the liquid

phase after which it returns to the solid phase.

We have found that the conversion of the dry powder into a fused film not only serves to secure the coating to the substrate but also provides a means by which the distribution of the coating material over the substrate may be made more even. In some cases the coating material may have such a low viscosity when fused that the coating will distribute itself evenly over a substrate but in most cases the coating material will be more viscous and the method therefore preferably includes the further mechanical treatment of the coating to even out the depth of the coating over the surface of the substrate. The evening out step may be carried out by passing the substrates under a vibrating plate or a 15 rotating roller, the plate or roller contacting and evening out the coating on the substrate. Alternatively the evening out step may be carried out by passing the substrates under a jet of air, for example an air knife, the curtain of air generated as the air knife evening out the coating on the substrate; the air may be heated in 20 order to avoid premature solidifying of the coating.

The dry powder coating is preferably converted into a fused film by heating, preferably by infra red radiation, but other forms of electromagnetic radiation may be used. Also the conversion into a fused film may be achieved partly or wholly by reducing the pressure of the region. Usually the change in the coating upon heating will simply be a physical change from a powder to

15

a liquid and then, on cooling, to a continuous solid coating, but there are other possibilities: for example, the powder coating may comprise a polymer which is cured during the treating step, for example by irradiation 5 with energy in the gamma, ultra violet or radio frequency bands, to form a continuous cross-linked polymer coating.

It is preferable to charge the powder to an appropriate electric potential, which may be positive or negative. The powder is preferably charged as it is supplied to the region through which the conveying means passes. The charging may be carried out using a corona charging apparatus; another possibility is to charge the powder triboelectrically. One or more electrodes maintained at a selected potential which would normally be of the same sign as that of the powder (i.e. a positive potential if the powder is positively charged and a negative potential if the powder is negatively charged) are preferably provided above the conveying means in the region to which the powder is supplied. The 20 positioning of the electrodes and the potential(s) at which they are maintained influences the electric field in the region and therefore the path of the powder through the region.

The conveying means is preferably maintained at a potential which is either earth potential or of opposite 25 sign to the potential to which the powder is charged. The conveying means may have an electrically conducting upper surface on which the medicinal substrates rest.

20

most cases the substrates will be made of an electrically insulating material; they may be treated prior to application of the powder to make them more electrically conducting, for example by moistening the exterior of the substrate. Such moistening facilitates the maintenance of the exterior of the substrate at earth potential and thus facilitates the application of the powder to the core.

The method of the invention is not restricted to the

use of any particular form of coating material. On the

other hand, for good results, the dry powder preferably

has the following physical properties:

- (1) A particle, size in the range of 1 μ m to 1000 μ m and preferably in the range of 30 μ m to 80 μ m; a small particle size enables the powder to be evenly dispersed in the region to which it is supplied and through which the conveyor belt passes.
- (2) A relatively high resistivity in the range of $10^6~\Omega m$ to $10^{24}~\Omega m$ and preferably in the range of $10^{10}~\Omega m$ to $10^{14}~\Omega m$; a high resistivity facilitates maintenance of the powder charge but makes it harder to charge the powder.
- (3) A viscosity when in the liquid phase of less than 500 Pas and preferably less than 75 Pas; a low viscosity facilitates even spreading of the coating over the surface of the tablet core.

10

15

- (4) After conversion to a fused film, a tensile strength of more than 0.5 N/m² and preferably more than 3.5 N/m²; a reasonably strong and tough coating is required in order to protect the tablet during subsequent handling up to the administration of the tablet.
- (5) A melting point which lies in the range of 50°C to 180°C and preferably 60°C to 100°C. With a relatively low melting point less energy is required to convert the powder into the liquid phase and the risk of damage to the tablet core from heating is reduced. The latter point is of special importance when the drug in the tablet core is liable to be damaged if its temperature is increased substantially above room temperature.

Examples of materials which, alone or when blended with other materials, meet some or all of the five preferred properties listed above can be found in:

20 polyamides, polyalkenes, waxes, oils, polyesters, sugar alcohols, sugars, polyoxyethylenes and ethylene vinyl acetate copolymer. Examples of suitable sugar alcohols are: sorbitol and xylitol. Examples of suitable sugars are sucrose and lactose. A polyester having properties especially suitable for the method of the invention is polycaprolactone.

The materials indicated above may be modified by blending other materials with them so as to improve their

physical properties to match more closely the properties indicated above. One or more opacifiers, for example titanium dioxide, and/or colourants, for example aluminium lakes or dyes, may also be added to the formulation of the coating material.

The materials listed above fall into two categories:
the water soluble materials (polyoxyethylenes, sugars,
sugar alcohols) and the poorly soluble or insoluble
polymeric materials. If a coating is required to

10 dissolve quickly following administration, then a water
soluble material will generally be preferred whereas if a
delayed, controlled or modulated release of the drug is
required a poorly soluble or insoluble polymeric material
is likely to be advantageous.

An especially preferred sugar alcohol is xylitol, while an especially preferred polymeric material is a polyester, such as, for example polycaprolactone. In both cases, however, it may be desirable to add small quantities of other substances to improve the physical properties of the material.

In another aspect the present invention is not concerned exclusively with coating a substrate with a dry powder and provides a method of coating substrates of medicinal products including the following steps:

feeding the substrates onto a conveying means,

providing an electrode spaced above the conveying

means and extending along and across the conveying means

to define a box-like region between the electrode and the

WO 92/14451 PCT/GB92/00323

- 12 -

conveying means, and maintaining the electrode at a first electric potential,

supplying coating material to the box-like region and electrically charging the coating material to a second electric potential,

conveying the substrates on the conveying means through the region with the conveying means and/or the substrates maintained at a different electric potential from the coating material and the electrode, whereby the coating material is attracted to the exposed surfaces of the substrates.

The invention may be used to apply a coating of controlled thickness and may be employed for a medicinal product containing a drug that is to be instantaneously released when administered or that is to be the subject of controlled or modulated release, such control or modulation being achieved from the nature of the coating and/or from the nature of the core. Where the desired form of release is to be achieved by characteristics of the coating, it may be preferred to leave one portion of the product uncoated or coated with a different material. In the case of a tablet having faces at opposite ends connected by a cylindrical side wall, the portion that is uncoated or coated with a different material may be one of the faces of the tablet, a small portion of one of the faces or a side wall of the tablet.

As has already been made clear, the methods described above have the advantage that they can be carried out continuously. They can therefore be employed as part of a continuous process for producing coated medicinal products, especially pharmaceutical tablets.

Thus, the present invention provides a continuous process for producing coated tablets comprising the steps of:

continuously forming pharmaceutical tablet cores on a rotary press, and

continuously coating the tablet cores by a method as 10 defined above.

The present invention also provides an apparatus for coating medicinal substrates of medicinal products with a dry powder, the apparatus including:

a conveying means,

means for feeding substrates onto the conveying means,

a feed for supplying dry powder to a region through which the conveying means passes,

electric charging means for electrically charging

the powder and/or the conveying means and/or the substrates such that the potential of the powder supplied to
the region through which the conveying means passes is
different from the potential of the substrates on the
conveying means,

means for treating dry powder coatings on the substrates to convert the powder into a fused film secured to the substrates.

The present invention also provides a medicinal

WO 92/14451 PCT/GB92/00323

- 14 -

product when coated by a method as described above and a medicinal product when produced by a method as described above.

A method and apparatus for electrostatic coating of tablet cores will now be described by way of example with reference to the accompanying drawings of which:

- Fig. 1 is a schematic side view of an apparatus for coating tablets on one face,
- Fig. 2 is a block diagram of a continuous process

 for manufacturing coated tablets employing
 the apparatus of Fig. 1, and

Fig. 3 to is additional view of a coated tablet.

The apparatus shown in Fig. 1 includes a conveyor belt 1 which is guided around three idler rollers 2 and a drive roller 3 driven by a motor 4 in the direction shown by an arrow in Fig. 1. A booth 5 is provided enclosing most of the upper run of the conveyor belt 1.

15

apparatus for feeding tablet cores to the upstream end (the left hand end as seen in Fig. 1) of the conveyor belt 1 outside the booth 5 is provided, but is not shown in the drawing. The form of such apparatus is not part of the present invention. A feed 6 for supplying dry powder to the interior of the booth above the conveyor belt is also provided. In the example of the invention illustrated the feed 6 comprises an electrostatic powder gun employing a single fixed corona electrode 7 mounted at the end of the gun barrel 8 and connected to a voltage supply 9. A mixture of powder and air is fed to the gun

barrel from a venturi powder feed 10.

Suspended from the top of the booth is an electrode 11 which is rectangular in plan view and extends across the whole width of the conveyor belt 1 and a portion of its length. The electrode 11 is connected to a voltage supply 12. Immediately below and supporting the conveyor belt 1 in the region below the electrode 11 is another rectangular electrode 18 which is connected to earth. The conveyor belt 1 is made of a laminate of polyvinyl-chloride and aluminium foil with the aluminium foil forming the outer layers of the belt and the belt is connected to earth.

An infra red heater 13 and a vibrating plate 14 are provided over the downstream end of the conveyor belt.

15 In use of the apparatus, pharmaceutical tablet cores are fed onto the upstream end of the belt 1 by a feed, 6 and pass along the conveyor with one face of the core resting on the belt and the other facing upwards. Dry powder with which the tablet cores are to be coated is sprayed into the booth 5 by the spray gun 1 which 20 charges the powder to a suitable potential (for this example it will be assumed that the powder is charged to a positive potential). Powder sprayed from the gun 1 enters the region between the electrode 11, which is 25 maintained at a positive potential, and the conveyor belt 1 and electrode 18 both of which are earthed. powder is directed downwardly away from the electrode 11 towards the conveyor belt 1 and the electrode 18. A

coating of powder is therefore laid over the conveyor belt and the tablet cores on the conveyor belt.

The tablet cores are then passed under the infra red heater 13 which heats the coating of powder on the 5 tablets sufficiently to cause the coating to melt and form a film coating over the upper side of the tablet core. As the tablets are carried beyond the heater 13 they are contacted by the vibrating plate 14 which evens out the coating. Thereafter, the film coating solidifies.

In order to provide a coating on the other side of the tablet core (if one is desired), the tablets are laid the other way up on a further conveyor arrangement similar to that shown in Fig. 1 and the process described 15 above with respect to Fig. 1 is repeated. Apparatus for transferring tablets from one conveyor to another and for turning them over in the course of the transfer is already known (see for example Figs. 2 and 3 of GB 1 075 404).

Referring now to Fig. 2, it will be seen that with the apparatus and method just described a continuous 20 production of coated tablets can be provided. Tablet cores produced for example from a high speed rotary press are fed directly to the apparatus of Fig. 1 where their upper faces are coated with electrically charged dry powder. The dry powder coating is then melted by heating, the partially coated tablets allowed to cool and fed to another apparatus of the kind shown in Fig. 1 but with their uncoated faces now uppermost. Those uncoated

faces are coated with electrically charged dry powder, the dry powder coating is melted by heating and the coated tablet allowed to cool and then fed to appropriate packaging machinery. Such a process can operate continously.

Fig. 3 shows a tablet having an upper face 15, a lower face 16, and a cylindrical side wall 17. In the first coating stage, one of the faces, say the face 15, is coated fully and the side wall 17 receives some powder coating but not a full coating. In the second coating stage the other face 16 is coated fully and the remainder of the coating to the side walls 17 is applied.

Claims:

- 1.: A method of coating substrates of medicinal products with a dry powder, the method including the following steps:
- feeding the medicinal substrates onto a conveying means;

supplying the dry powder to a region through which the substrates are to be conveyed on the conveying means;

conveying the medicinal substrates on the conveying

means through the region with the conveying means and/or
the substrates maintained at a different electric
potential from the dry powder, whereby the dry powder is
attracted to the exposed surfaces of the substrates but
is unable to reach the surfaces of the substrates in

contact with the conveying means, and

treating the dry powder coatings to convert the powder into a fused film secured to the substrates.

- 2. A method according to claim 1, in which the method is carried out as a continuous process.
- 20 3. A method according to claim 1 or 2, including the following further subsequent steps:

feeding the medicinal substrates onto a conveying
means with the treated powder coatings of the substrates
in contact with the conveying means and with that surface
of the substrate that was in contact with the conveying
means during the above-mentioned conveying step exposed;
supplying the dry powder with which the substrates

25

are to be coated to a region through which the conveying means passes;

conveying the substrates on the conveying means through the region with the conveying means and/or the substrates maintained at a different electric potential from the dry powder whereby the dry powder is attracted to the exposed surfaces of the substrates but is unable to reach the coated surfaces of the substrates in contact with the conveying means, and

treating the dry powder coatings to convert the newly applied powder into a fused film secured to the substrates.

- 4. A method according to claim 3, in which the conveying means used during the second coating stage is not the one used during the first coating stage.
- 5. A method according to any preceding claim, in which the conveying means comprises a conveyor belt.
- 6. A method according to any preceding claim including a further mechanical treatment of the coating to even out the depth of the coating over the surface of the substrate.
 - 7. A method according to claim 6, in which the evening out step is carried out by passing the substrates under a vibrating plate or a rotating roller, the plate or roller contacting and evening out the coating on the substrate.
 - 8. A method according to claim 6, in which the evening out step is carried out by passing the substrates

WO 92/14451 PCT/GB92/00323

- 20 -

under a jet of air.

- 9. A method according to any preceding claim, in which the dry powder coating is converted into a fused film by heating.
- 5 10. A method according to any preceding claim, in which the powder is electrically charged.
 - 11. A method according to claim 10, in which the powder is charged as it is supplied to the region through which the conveying means passes.
- 10 12. A method according to claim 10 or 11, in which the charging is carried out using a corona charging apparatus.
 - 13. A method according to any preceding claim, in which one or more electrodes maintained at a selected
- potential are provided above the conveying means in the region to which the powder is supplied.
 - 14. A method according to any preceding claim, in which the powder has a particle size in the range of 1 μm to 1000 μm .
- 20 15. A method according to any preceding claim, in which the powder has a relatively high resistivity in the range of 10^6 to $10^{24}~\Omega m$.
- 16. A method according to any preceding claim, in which the powder has a viscosity when in the liquid phase 25 of less than 500 Pas.
 - 17. A method according to any preceding claim, in which the powder has, after returning to the solid phase, a tensile strength of more than $0.5~N/m^2$.

25

- 18. A method according to any preceding claim, in which the powder has a melting point which lies in the range of 50°C to 180°C.
- 19. A method according to any preceding claim, in which the dry powder consists wholly or substantially of one or more of the materials in the group comprising: polyamides, polyalkenes, waxes, oils, polyesters, polyoxyethylenes, sugars, sugar alcohols and ethylene vinyl acetate copolymer.
- A method according to claim 19, in which the dry powder consists wholly or substantially of xylitol.
 A method according to claim 19 in which the dry
 - powder consists wholly or substantially of polycaprolactone.
- 15 22. A method of coating substrates of medicinal products including the following steps:

feeding the substrates onto a conveying means, providing an electrode spaced above the conveying means and extending along and across the conveying means to define a box-like region between the electrode and the conveying means, and maintaining the electrode at a first electric potential,

supplying coating material to the box-like region and electrically charging the coating material to a second electric potential,

conveying the substrates on the conveying means through the region with the conveying means and/or the substrates maintained at a different electric potential

- 22 -

from the coating material and the electrode, whereby the coating material is attracted to the exposed surfaces of the substrates.


- 23. A method according to any preceding claim in 5 which the substrates are pharmaceutical tablet cores.
 - A continuous process for producing coated tablets comprising the steps of:

continuously forming pharmaceutical tablet cores on a rotary press, and

- 10 continuously coating the tablet cores by a method according to any preceding claim.
 - 25. An apparatus for coating substrates of medicinal products with a dry powder, the apparatus including: a conveying means,
- 15 means for feeding substrates onto the conveying means,
 - a feed for supplying dry powder to a region through which the conveying means passes,
- electric charging means for electrically charging 20 the powder and/or the conveying means and/or the substrates such that the potential of the powder supplied to the region through which the conveying means passes is different from the potential of the substrates on the conveying means,
- 25 means for treating dry powder coatings on the substrates to convert the powder into a fused film secured to the substrates.
 - A medicinal product when coated by a method 26.

according to any one of claims 1 to 23.


27: A tablet when produced by a method according to claim 24.




S .

4

2/2





	<u> </u>		International Application No			
I. CLASSII	FICATION OF SUBJE	ECT MATTER (If several classification sy	with apply, indicate all) ⁶			
	to International Patent. 5 A61K9/28	Classification (IPC) or to both National Cl B05B5/08;	assification and IPC B05D1/06			
				·		
II. FIELDS	SEARCHED					
		Minimum Docume	atation Searched			
Classificat	ion System		Classification Symbols			
Int.Cl	. 5	B05D; B05B;	B05C; A61K			
		Documentation Searched other t to the Extent that such Documents a				
III. DOCU	MENTS CONSIDERE	D TO BE RELEVANT?				
Category °	Citation of Do	cument, Il with indication, where appropria	to, of the relevant passages 12	Relevant to Claim No.13		
X Y		495 217 (SCHRUM T.S.) 2		1-5, 9-11,13, 22-27		
	ř	whole document		<u>y</u>		
Y	1988	774 102 (KIEFER S.L. ET umn 8, line 15 - line 5!		12		
x	1964 cited in & GB,A,	9 491 (TANABE SEIYAKU Con the application 1075404 whole document	D,LTD) 16 October	1-5, 9-11,13, 22-27		
A	BE,A,522 see page	2 840 (UNILEVER N.V.) 19 e 1, line 1 - line 10	5 October 1953	6,7		
"To later document published after the international filing date or priority date and not in conflict with the application but considered to be of particular relevance investion investion." "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published after the international filing date or priority date and not in conflict with the application but investion or priority date and not in conflict with the application but decument of particular relevance; the claimed invention cannot be considered as ovel or cannot be considered to involve an inventive step when the decument is combined with one or more other such decuments, such combination being obvious to a person skilled in the art. "A" document member of the same patent family						
IV. CERTI	FICATION					
Date of the	·	he International Search JUNE 1992	Date of Mailing of this International Searce 22, 06, 92	h Report		
Internations	i Searching Authority	· · · · · · · · · · · · · · · · · · ·	Signature of Authorized Officer	,		
FIROPEAN PATENT OFFICE			Reelow			

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)						
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.				
	GB,A,1 449 993 (AMERICAN CAN COMPANY) 15 September 1976 see claims	6,7				
	EP,A,O 381 044 (HOECHST A.G.) 8 August 1990					
	EP,A,O 405 884 (THE PROCTER & GAMBLE COMPANY) 2 January 1991					
	DE,A,2 636 152 (PFRIMMER J. & CO) 6 October 1977 see column 2, line 23 - line 42 see column 4; example 1	19,20				
	EP,A,O 085 149 (ELECTROSTATIC DEPOSITION TECHNOLOGIES) 10 August 1983					
	*	*				

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO. GB SA

9200323 56848

This names lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 01/06/92

Patent document cited in search report	Publication date		Potent family member(s)		
US-A-4495217	22-01-85	None			
US-A-4774102	27-09-88	CA-A- US-A-	1262081 4779564	03-10-89 25-10-88	
BE-A-649491	16-10-64	CH-A- DE-B- FR-A- GB-A- NL-A-	409246 1204776 1533164 1075404 6406815	21	-12-64
BE-A-522840		None		à.	
GB-A-1449993	15-09-76	AU-A- CA-A- JP-C- JP-A- JP-B-		01· 28· 24·	-01-76 -08-78 -10-83 -05-75 -02-83
EP-A-0381044	08-08-90	DE-A- US-A-	3903235 5024819		-08-90 -06-91
EP-A-0405884	02-01-91	US-A- AU-A- CA-A- CN-A- JP-A-	5000978 5796790 2018982 1048885 3137200	03- 29- 30-	-03-91 -01-91 -12-90 -01-91 -06-91
DE-A-2636152	06-10-77	AT-B- AU-B- AU-A- BE-A- CA-A- CH-A- FR-A, B GB-A- JP-C- JP-A- JP-B- NL-A-	352884 510921 2768777 857659 1086650 630259 2361105 1547527 1134821 53020416 57025007 7708808	17- 15- 01- 30- 15- 10- 20- 14- 24- 27-	·10-79 ·07-80 ·02-79 ·12-77 ·09-80 ·06-82 ·03-78 ·06-79 ·02-83 ·02-78 ·05-82 ·02-78
more éstails about this ances : :					